An investigation on behalf of investors of Solid Biosciences Inc. (NASDAQ: SLDB) shares over potential securities laws violations by Solid Biosciences Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Solid Biosciences Inc. (NASDAQ: SLDB) concerning whether a series of statements by Solid Biosciences Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. Solid Biosciences Inc. conducted its initial public offering (IPO) in January 2018. Solid Biosciences Inc. sold 7.81 million shares at $16.00 per share.

Shares of Solid Biosciences Inc. (NASDAQ: SLDB) rose to as high as $45.85 per share in October 2018.

Since then shares of Solid Biosciences Inc. (NASDAQ: SLDB) declined to as low as $1.96 per share in March 2020.